Cunha-Vaz J G, Mota C C, Leite E C, Abreu J R, Ruas M A
Arch Ophthalmol. 1985 Sep;103(9):1307-11. doi: 10.1001/archopht.1985.01050090059032.
To study the effect of sulindac on the alteration of the blood-retinal barrier, 24 insulin-dependent diabetic patients with minimal or no retinopathy were randomly assigned to receive either oral sulindac (200 mg twice daily) or a placebo for a period of six months. All patients underwent fundus photography, fluorescein angiography, and vitreous fluorophotometry before treatment and after 1, 3, and 6 months of treatment. Vitreous fluorophotometry data showed that there were fewer alterations of the blood-retinal barrier in the sulindac group compared with the placebo group during the six-month study period.
为研究舒林酸对血视网膜屏障改变的影响，24例胰岛素依赖型轻度或无视网膜病变的糖尿病患者被随机分为两组，分别口服舒林酸（每日两次，每次200毫克）或安慰剂，为期6个月。所有患者在治疗前以及治疗1、3和6个月后均接受了眼底照相、荧光素血管造影和玻璃体荧光光度测定。玻璃体荧光光度测定数据显示，在为期6个月的研究期间，舒林酸组血视网膜屏障的改变少于安慰剂组。
